A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) PLUS Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies
A study for patients with Multiple Myeloma using study drug Selinexor
Sponsor: Karyopharm Therapeutics, Inc
Enrolling: Male and Female Patients
IRB Number: AAAP1309
U.S. Govt. ID: NCT02336815
Contact: Ryan Shelton: 212-304-5485 / rs3323@columbia.edu
Additional Study Information: This is research study for patients who have been newly diagnosed with Multiple Myeloma (MM). Their previous treatments have not been successful and their cancer is progressing. The purpose of this research study is to see if the study drug selinexor (KPT-330) has any effects against their cancer. This study combines the use of two drugs, selinexor (KPT-330) and dexmethasone, for treatment of Multiple Myeloma. The study drug selinexor (KPT-330) works by trapping "tumor suppressing proteins" within the cell and thus causing the cancer cells to die or stop growing.
This study is closed
Suzanne Lentzsch, MD
Do You Qualify?
Do you have symptomatic multiple myeloma? Yes No
Do you have smoldering multiple myeloma? Yes No
Do you have plasma cell leukemia? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Ryan Shelton